Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several dosing-related claims for adult plaque psoriasis and generalization about maintenance intervals are not fully supported or are contradicted by the provided label excerpts, including an important error in the loading-to-maintenance timing framing.
Category Scores
Accurate Statements
Cosentyx dosing depends on the condition being treated.
2.3 vs 2.4 vs 2.8 (different recommended dosage/regimens by condition).
In the psoriasis schedule, 300 mg is given as two 150 mg injections to reach the full dose.
2.3 (Each 300 mg dosage is given as one 300 mg injection or as two 150 mg injections).
Cosentyx is available in different injection formats.
3 (subcutaneous presentations: UnoReady pen, Sensoready pen, prefilled syringes 300 mg/2 mL and 150 mg/mL; pediatric 75 mg/0.5 mL; and IV use vial solution).
Unsupported Statements
The exact maintenance interval for Cosentyx can differ by condition.
Not supported by the provided label excerpts; PsO (2.3), PsA (2.4), and nr-axSpA (2.8) show every-4-weeks maintenance intervals in the excerpted text.
Dosing instructions for missed Cosentyx doses depend on the time since the missed injection and the specific regimen, including whether the patient is in the loading or maintenance phase.
Missed-dose instructions are not present in the provided label excerpts.
For other adult inflammatory conditions, Cosentyx dosing is commonly 150 mg or 300 mg with loading and then maintenance at fixed intervals.
The excerpts support fixed every-4-weeks intervals and provide examples (including some loading regimens), but do not substantiate the broad framing that 'other adult inflammatory conditions' commonly use '150 mg or 300 mg' with loading for all such conditions.
After the loading period for many adult regimens, maintenance dosing intervals are often every 4 weeks for plaque psoriasis.
The label supports every-4-weeks 'thereafter' dosing for plaque psoriasis, but the claim is indirect ('often' / 'after the loading period') rather than stated exactly as in the excerpt.
Contradictions
Low
AI Statement
For adult plaque psoriasis, after the loading phase, Cosentyx 300 mg is administered every 4 weeks starting at week 4.
Label Reference
2.3 (300 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter).
Important Omissions
Plaque psoriasis dosing includes Week 4 in the initial schedule (Weeks 0–4), followed by every 4 weeks thereafter.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The provided excerpts show a specific plaque psoriasis schedule including Week 4 in the initial dosing; the response misframes the loading-to-maintenance transition ('starting at week 4'), which could lead to dosing interval/timing errors.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Plaque psoriasis loading-to-maintenance timing is misstated; initial dosing includes Week 4 and maintenance is 'every 4 weeks thereafter.'
Suggested Improvement
State plaque psoriasis dosing as 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, then every 4 weeks thereafter; note that 300 mg may be given as one 300 mg injection or two 150 mg injections.